Stereotactic radiosurgery for brain metastases

Brain metastases (BM) represent an increasingly common challenge in the treatment of metastatic cancer. With improvements in both systemic and intra-cranial treatment, the incidence and prevalence of BM continues to rise; the incidence of brain metastases in patients with metastatic cancer has been estimated as high as 30-40%.

Historically, management of brain metastases revolved around palliative care coupled with whole brain radiation (WBRT) for selected fit patients. However, with patients surviving longer with systemic metastases, coupled with increased screening detection of brain metastases at an earlier stage in the patient’s cancer journey, stereotactic radiosurgery (SRS) plays an increasing role in management of BM patients, as sole first-line treatment as well as salvage treatment after initial SRS or WBRT.

The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.